arises particularly from the fact2 that the circulating level of PTH, which should be defined as the biologically active hormone and not by an immunological response to unidentified antigenic fragments of FPTH or to other molecules which may be unrelated to PTH, cannot be above about 20 pg/ml. Yet even the best generally current radioimmunoassay of PTH cannot measure less than about 150 pg/ml, so that normal levels of 70-450 pg/ml (based on the 1-34 PTH and therefore equivalent to about 140-900 pg/ml of the intact hormone) in an assay based on the biologically active N-terminal region of the molecule,3 are not instructive of the true circulating levels of this hormone. Thus while we were aware of many radioimmunoassays of PTH in these diseases, and of the unwarranted conclusions derived from such studies, we were unwilling to quote more than a few selected examples. We certainly did not wish to give offence by discussing work, such as that by Pawlotsky and colleagues, in which an antibody directed to the C-terminus was used (which detects biologically inactive fragments which have an inordinately long half-time in the circulation4) and in which normal circulating levels are recorded in nanograms per millilitre, namely about 500 times more 'PTH' than can actually be circulating. It is on this basis that we made the statement, to which Pawlotsky and colleagues take exception, that our study 'has shown a wide disparity between the circulating levels of biologically active parathyroid hormone and the levels of immunoreactive hormone previously reported by others'. We con-. sider a 500-fold difference to represent 'a wide disparity'.
Targeting steroid therapy in rheumatoid arthritis SIR, As reported previously,' we have incorporated dexamethasone palmitate into a lipid microsphere (liposteroid). Like a liposome, the lipid microsphere is easily taken up by phagocytes. Therefore liposteroid accumulates in inflamed tissues and has a much stronger antiinflammatory activity than free dexamethasone in rats. ' In order to discover whether or not liposteroid could be used clinically as 'targeting' therapy we carried out a double-blind cross-over test with liposteroid in rheumatoid arthritis. Thirty-six patients with classical or definite rheumatoid arthritis defined by ARA criteria (9 male and 27 female, average age 50 5 years) entered the study. Four types of 1 ml ampoules were prepared: A=liposteroid containing 2 5 mg dexamethasone, B=liposteroid placebo, C=dexamethasone disodium phosphate (Merck) containing 3-3 mg dexamethasone, and D=saline. The patients were treated randomly with 1 ml intravenous injections of either A or B and intramuscular D or C. Two to 3 weeks later they were given B or A and C or D. The effectiveness of steroid was evaluated by the degree and duration of subjective improvement in joint symptoms and morning stiffness and preference of patients for each treatment. In this study the degree of improvement of joint symptoms was arbitrarily recorded as very (+ +), moderately (+), slightly (±), or not (-) improved, and the preference of patients was also recorded as much better, better, or similar.
The results are shown in Tables 1 and 2 . Although the degree of improvement in joint symptoms on 3 days was not so different in the 2 groups, the average duration of effectiveness in joint symptoms and morning stiffness was longer in patients on liposteriod than in those on free dexamethasone. As to the preference of patients for each group, liposteroid was significantly more preferable than free dexamethasone. As shown in Table 2 
